What is the history of Progressive Osseous Heteroplasia?

Progressive Osseous Heteroplasia (POH) was first formally described in medical literature in 1994 by Dr. Edward M. Kaplan and colleagues, who distinguished it from other forms of heterotopic ossification. Since its discovery, medical understanding of Progressive Osseous Heteroplasia has shifted from viewing it as a generalized bone disorder to identifying it as a specific genetic condition caused by loss-of-function mutations in the GNAS gene.

Who first identified Progressive Osseous Heteroplasia?

While cases of abnormal bone formation had been noted in clinical settings previously, the condition was formally characterized as a distinct clinical entity by Dr. Edward M. Kaplan in 1994. Before this classification, patients with Progressive Osseous Heteroplasia were often misdiagnosed with more common conditions like fibrodysplasia ossificans progressiva (FOP) or Albright hereditary osteodystrophy. The recognition of Progressive Osseous Heteroplasia allowed clinicians to differentiate it by the specific pattern of dermal ossification and deep connective tissue involvement.

How has our understanding of Progressive Osseous Heteroplasia evolved?

The history of this condition is defined by the transition from descriptive clinical observation to molecular genetic diagnosis. Key milestones include:

• 1994: First clinical definition of Progressive Osseous Heteroplasia provided by Kaplan et al.


• 2002: Researchers identified that inactivating mutations in the GNAS gene are the primary cause, linking Progressive Osseous Heteroplasia to the broader spectrum of GNAS-related disorders.


• 2010s-Present: Advanced imaging and genomic sequencing have allowed for earlier diagnosis, which is crucial for managing the progression of heterotopic ossification.

What were the historical misconceptions about the disease?

Historically, Progressive Osseous Heteroplasia was frequently confused with other ossifying conditions. A major misconception was that the bone formation observed in patients was merely a secondary result of trauma or inflammation. We now know that in Progressive Osseous Heteroplasia, the bone formation is a primary, genetically programmed process that occurs in the skin and subcutaneous tissues, often occurring without any injury at all.

How has patient advocacy changed the landscape?

The rarity of the condition—with fewer than 100 cases reported in medical literature—once led to significant isolation for families. Today, platforms like DiseaseMaps.org help connect the small global community of patients, allowing individuals with Progressive Osseous Heteroplasia to share lived experiences and advocate for focused research. This connectivity is vital for a condition where clinical expertise is concentrated in only a few specialized centers worldwide.

Next steps

• Consult a medical geneticist or an endocrinologist specializing in mineral metabolism.


• Connect with the rare disease community at DiseaseMaps.org to find support and shared experiences.


• Monitor for new clinical trials or studies via the NIH GARD database.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Progressive osseous heteroplasia.


• OMIM (Online Mendelian Inheritance in Man): Entry #166350 (Progressive Osseous Heteroplasia).


• Orphanet: Rare disease database entry for Progressive Osseous Heteroplasia.


• Kaplan, E. M., et al. (1994). "Progressive osseous heteroplasia: a distinct developmental disorder of heterotopic ossification."